Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
AKLI Akili
1.610+0.030+1.90%
Trading Session
02/01 15:14 ET
High
1.630
Open
1.630
Turnover
46.96K
Low
1.570
Pre Close
1.580
Volume
29.59K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Akili (NASDAQ:AKLI) Price Target Raised to $3.00
Akili (NASDAQ:AKLI – Get Rating) had its price target boosted by Morgan Stanley from $2.00 to $3.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an "
Morgan Stanley Sticks to Its Hold Rating for Akili (AKLI)
Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating
10:28 AM EST, 01/25/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Akili Is Maintained at Equal-Weight by Morgan Stanley
Akili Is Maintained at Equal-Weight by Morgan Stanley
Akili Price Target Raised to $3.00/Share From $2.00 by Morgan Stanley
Akili Price Target Raised to $3.00/Share From $2.00 by Morgan Stanley
Akili Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/25/2023 129.01% Morgan Stanley $2 → $3 Maintains Equal-Weight 12/28/2022 52.67% Morgan Stanley → $2 Ini
Morgan Stanley Maintains Equal-Weight on Akili, Raises Price Target to $3
Morgan Stanley analyst Vikram Purohit maintains Akili (NASDAQ:AKLI) with a Equal-Weight and raises the price target from $2 to $3.
LifeSci Capital Reaffirms Their Buy Rating on Akili (AKLI)
Akili Cuts Workforce by 30% to Reduce Costs
01:24 PM EST, 01/12/2023 (MT Newswires) -- Akili (AKLI) is laying off 46 employees representing about 30% of its workforce in an effort to reduce costs, the company said Thursday in a regulatory filin
Akili to Champion Digital Therapeutics in Conjunction With J.P. Morgan Healthcare Conference
Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongside the J.P. Morgan Healthcare Conference in
Company Overview
More
Akili, Inc.(formerly Social Capital Suvretta Holdings Corp. I) , a commercialized company that develops digital therapies that combine science and technology to address cognitive disorders such as patient inattention, memory loss, difficulty learning new skills, and difficulty making decisions, is a new category of software-based medicine. The company has used its approach to technology that targets the brain directly to build a new class of drugs - drugs that have been validated in clinical trials, such as drugs or medical devices. The company's platform is powered by a proprietary therapeutic engine designed to target cognitive disorders in the brain, informed by decades of research and validated by a rigorous clinical program.
CEO： Dr. W. Edward Martucci, PhD
Market： NASDAQ
Listing Date： 06/30/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet